{"id":"ribavarin","rwe":[],"tags":[],"phase":"discontinued","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":["Anemia","Asthma","Autoimmune hepatitis","Bone marrow depression","Breastfeeding (mother)","Chronic obstructive lung disease","Cirrhosis of liver","Constitutional aplastic anemia","Coronary arteriosclerosis","Hb SS disease","Hemolytic anemia","Impaired renal function disorder","Interstitial pneumonia","Myocardial infarction","Myocardial ischemia","Pancreatitis","Pancytopenia","Periodontitis","Pregnancy, function","Pulmonary Infiltrates","Sarcoidosis","Thalassemia"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"discontinued","trials":["NCT00842205","NCT00881582","NCT00703872","NCT02204475","NCT00249860","NCT03465280","NCT03797066","NCT01805882"],"aliases":["Copegus","Rebetol"],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"brandName":"Ribavarin","companyId":"charles-university-czech-republic","ecosystem":[],"mechanism":{"target":"Cytosolic purine 5'-nucleotidase, Adenosine kinase, Ectonucleotide pyrophosphatase/phosphodiesterase family member 1","novelty":"","modality":"Small molecule","drugClass":"","explanation":"","oneSentence":"","technicalDetail":""},"commercial":null,"references":[],"biosimilars":[],"companyName":"Charles University, Czech Republic","competitors":[],"dataSources":[{"url":"https://clinicaltrials.gov","name":"ClinicalTrials.gov","fields":["trialDetails","trials"],"retrievedDate":"2026-04-07"},{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"Ribavarin","indications":{"approved":[{"name":"Chronic hepatitis C","diseaseId":"chronic-hepatitis-c","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Compensated cirrhosis","diseaseId":"compensated-cirrhosis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Respiratory syncytial virus infection","diseaseId":"respiratory-syncytial-virus-infection","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT00842205","phase":"NA","title":"Role of Heme Oxygenase in the Pathogenesis od Hepatocellular Injury in Chronic HCV Infection","status":"UNKNOWN","sponsor":"Charles University, Czech Republic","isPivotal":false,"enrollment":150,"indication":"Chronic HCV Infection, Nonalcoholic Steatohepatitis","completionDate":"2009-12"},{"nctId":"NCT00881582","phase":"Phase 4","title":"Peginterferon Alfa-2a Plus Ribavirin Combination Treatment in Chronic Hepatitis C Post-Renal Transplant Patients","status":"COMPLETED","sponsor":"King Abdulaziz Medical City","isPivotal":false,"enrollment":32,"indication":"Chronic Hepatitis C, Renal Transplant","completionDate":"2011-12"},{"nctId":"NCT00703872","phase":"Phase 2","title":"An Evaluation of Two Dose Routes of HDV-Interferon Administered With Ribavarin in the Treatment of Chronic Hepatitis C Nonresponders and Naive Hepatitis C Patients","status":"UNKNOWN","sponsor":"Hepasome Pharmaceuticals","isPivotal":false,"enrollment":50,"indication":"Chronic Hepatitis C","completionDate":"2009-12"},{"nctId":"NCT02204475","phase":"Phase 3","title":"A Phase III, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 Versus Boceprevir/Pegylated Interferon/Ribavirin (PR) in Treatment-Naïve and PR Pr","status":"WITHDRAWN","sponsor":"Merck Sharp & Dohme LLC","isPivotal":true,"enrollment":0,"indication":"Hepatitis C","completionDate":"2016-09"},{"nctId":"NCT00249860","phase":"Phase 3","title":"A Multicentre Phase III Study of Interferon-beta-1a for the Treatment of Chronic Hepatitis C in Asian Subjects","status":"COMPLETED","sponsor":"EMD Serono","isPivotal":true,"enrollment":257,"indication":"Hepatitis C","completionDate":"2005-08"},{"nctId":"NCT03465280","phase":"N/A","title":"Airway Intervention Registry (AIR) Extension: Recurrent Respiratory Papillomatosis","status":"UNKNOWN","sponsor":"Newcastle-upon-Tyne Hospitals NHS Trust","isPivotal":false,"enrollment":400,"indication":"Recurrent Respiratory Papillomatosis, Human Papilloma Virus","completionDate":"2022-08-31"},{"nctId":"NCT03797066","phase":"Phase 4","title":"Localized on -Site Testing and Treatment of Hepatitis C in Homeless Persons in South London: a Pilot Non-randomised Phase 4 Interventional Clinical Trial of Grazoprevir and Elbasvir ± Ribavirin in Par","status":"TERMINATED","sponsor":"King's College Hospital NHS Trust","isPivotal":false,"enrollment":13,"indication":"Hepatitis C, Chronic","completionDate":"2020-11-30"},{"nctId":"NCT01805882","phase":"Phase 2","title":"A Pilot Study to Evaluate the Safety and Efficacy of Multiple Anti-HCV Combination Therapy in Chronically Infected Hepatitis C Patients","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","isPivotal":false,"enrollment":229,"indication":"Hepatitis C, Chronic","completionDate":"2015-08"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"formularyStatus":[],"apiManufacturers":[],"developmentCodes":[],"ownershipHistory":[],"therapeuticAreas":["Infectious Disease"],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"genericManufacturerList":[],"modality":"Small molecule","aiSummary":"","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}